COST CONSEQUENCE ANALYSIS OF DIABETIC NEPHROPATHY MANAGEMENT IN A TERTIARY CARE HOSPITAL

SARA KURIEN; MANOHAR V R; SHARATH KUMAR K; ARUN RAVINDRAN

doi:10.22159/ajpcr.2023.v16i1.46163

Authors

SARA KURIEN Department of Pharmacology, Azeezia Medical College, Kollam, Kerala, India.
MANOHAR V R Department of Pharmacology, A. J. Institute of Medical Sciences, Mangaluru, Karnataka, India.
SHARATH KUMAR K Department of Pharmacology, A. J. Institute of Medical Sciences, Mangaluru, Karnataka, India.
ARUN RAVINDRAN Senior Medical Safety Lead, Chief Medical Office and Patient Safety, Novartis Healthcare, Hyderabad, Telangana. India.

DOI:

https://doi.org/10.22159/ajpcr.2023.v16i1.46163

Keywords:

Type 2 DM, Diabetic nephropathy, CKD, Pharmacoeconomics, Cost consequence analysis, Direct costs, Indirect medical costs, India

Abstract

Objective: The objective of the study was to assess the overall costs incurred to patients with diabetic nephropathy (DN) and to disclose the elements that could affect them.

Methods: Two-year retrospective, observational study using hospital database of a tertiary care center in Mangalore. Outcomes were assessed based on the survival of patients, length of hospital stay, coexistence of risk factors, and comorbidities. Severity was identified through staging of the disease; costs and clinical outcomes assessed through the cost consequence analysis.

Results: Of the 156 patients who met the diagnostic criteria, it was noticed that demographic age factor for DN was declining and the minimum duration to develop DN was seen to be as less as 1–5 years. In spite of having ample evidence that angiotensin-converting enzyme inhibitors (ACEIs) and angiotensin receptor blockers (ARBs) control the progression of disease, not many doctors were inclined to follow. A study showed that patients of DN with chronic kidney disease (CKD) spent more and patients with CKD and end-stage renal disease (ESRD) spent double than those with CKD alone.

Conclusion: Overall costs in treating 156 patients of DN amounted to 10 lakh INR and the major determinant was the cost of investigations, unlike what was expected of the drug prices.

Downloads

Download data is not yet available.

Author Biographies

MANOHAR V R, Department of Pharmacology, A. J. Institute of Medical Sciences, Mangaluru, Karnataka, India.

Professor, Department of Pharmacology

SHARATH KUMAR K, Department of Pharmacology, A. J. Institute of Medical Sciences, Mangaluru, Karnataka, India.

Associate Professor, Department of Pharmacology

ARUN RAVINDRAN, Senior Medical Safety Lead, Chief Medical Office and Patient Safety, Novartis Healthcare, Hyderabad, Telangana. India.

Senior Medical Safety Lead

References

Ramachandran A, Das AK. Basic considerations of diabetes mellitus. In: Siddharth NS, Anand MP, editors. API Textbook of Medicine. 7th ed. Mumbai: The Association of Physicians of India; 2003.

Hendry BM, Viberti GC, Hummel S Bagust A, Piercy J. Modelling and costing the consequences of using an ACE inhibitor to slow the progression of renal failure in Type 1 diabetic patients. QJM 1997;90:277-82.

King H, Aubert RE, Herman WH. Global burden of diabetes, 1995-2025: Prevalence, numerical estimates, and projections. Diabetes Care 1998;21:1414-31.

Happich M, Landgraf R, Piehlmeier W, Falkenstein P, Stamenitis S. The economic burden of nephropathy in diabetic patients in Germany in 2002. Diabetes Res Clin Pract 2008;80:34-9.

Bootman JL, Townsend RJ, McGhan WF. Introduction to Pharmacoeconomics. In: Principles of Pharmacoeconomics. 3rd ed. New York: McGraw-Hill; 2008.

???. Current Index of Medical Specialities. Mumbai: UBM Medica India Private Limited; 2017.

Lisa ST. Pharmacoeconomics: Principles, methods, and applications. In: DiPiro JT, Talbert RL, Yee GC, Matzke GR, Wells BG, Posey L, et al.Pharmacotherapy: A Pathophysiologic Approach. 8th ed. New York: McGraw-Hill; 2011.

Fisher LD, Van Belle G, Heagerty PJ, Lumley T. Biostatistics: A Methodology for Health Sciences. New York: John Wiley and Sons; 1993.

Wild S, Roglic G, Green A, Sicree R, King H. Global prevalence of diabetes: Estimates for the year 2000 and projections for 2030. Diabetes Care 2004;27:1047-53.

Michael B, Lloyd PA, Eli F, Aaron IV, et al. Complications of diabetes mellitus. In: Larsen PR, Henry MK, Kenneth SP, Melmed S, editors. William’s Textbook of Endocrinology. 10th ed. Philadelphia: Saunders; 2003.

Available from: https://www.usrds.org

Bhaskaran VP, Rau NR, Satyashankar, Acharya RR, Metgud CS, Koshy T. A study of the direct costs incurred by Type-2 diabetes mellitus patients for their treatment at a large tertiary-care hospital in Karnataka, India. J Acad Hosp Adm 2003;15:12-22.

Satyavani K, Kothandan H, Jayaraman M, Viswanathan V. Direct costs associated with chronic kidney disease among Type 2 diabetic patients in India. Indian J Nephrol 2014;24:141-7.